Asset Details
Do you wish to reserve the book?
Engager T Cells: A New Class of Antigen-specific T Cells That Redirect Bystander T Cells
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Engager T Cells: A New Class of Antigen-specific T Cells That Redirect Bystander T Cells
Do you wish to request the book?
Engager T Cells: A New Class of Antigen-specific T Cells That Redirect Bystander T Cells
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Engager T Cells: A New Class of Antigen-specific T Cells That Redirect Bystander T Cells
2015
Overview
Adoptive immunotherapy with antigen-specific T cells has shown promise for the treatment of malignancies. However, infused T cells are unable to redirect resident T cells, limiting potential benefit. While the infusion of bispecific T-cell engagers can redirect resident T cells to tumors, these molecules have a short half-life, and do not self amplify. To overcome these limitations, we generated T cells expressing a secretable T-cell engager specific for CD3 and EphA2, an antigen expressed on a broad range of human tumors (EphA2-ENG T cells). EphA2-ENG T cells were activated and recognized tumor cells in an antigen-dependent manner, redirected bystander T cells to tumor cells, and had potent antitumor activity in glioma and lung cancer severe combined immunodeficiency (SCID) xenograft models associated with a significant survival benefit. This new class of tumor-specific T cells, with the unique ability to redirect bystander T cells, may be a promising alternative to current immunotherapies for cancer.
Publisher
Elsevier Inc,Elsevier Limited,Nature Publishing Group
Subject
/ Antigens
/ Antigens, Neoplasm - genetics
/ Antigens, Neoplasm - immunology
/ Brain Neoplasms - immunology
/ Bystander Effect - immunology
/ Cancer
/ Humans
/ Immunotherapy, Adoptive - methods
/ Kinases
/ Male
/ Medicine
/ Mice
/ Original
/ Receptor, EphA2 - immunology
/ T-Lymphocytes - transplantation
/ Tumors
